Indirect treatment comparison (ITC) of medical therapies for an overactive bladder.

about

Long-term adherence to clinical therapy of overactive bladder.

P2860

Q42332345-E2436B74-4B4C-4CCE-8AB0-4A6154EA8FA3

P2860

Indirect treatment comparison (ITC) of medical therapies for an overactive bladder.

Item

http://www.wikidata.org/entity/Q47433658

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Indirect treatment comparison (ITC) of medical therapies for an overactive bladder.

@en

Indirect treatment comparison

@nl

type

Item

label

Indirect treatment comparison (ITC) of medical therapies for an overactive bladder.

@en

Indirect treatment comparison

@nl

prefLabel

Indirect treatment comparison (ITC) of medical therapies for an overactive bladder.

@en

Indirect treatment comparison

@nl

P1476

Indirect treatment comparison (ITC) of medical therapies for an overactive bladder.

@en

P2093

Aneta Obloza

http://www.w3.org/2001/XMLSchema#string

Derrick Yates

http://www.w3.org/2001/XMLSchema#string

Joshua Kirby

http://www.w3.org/2001/XMLSchema#string

P2860

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women.

OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder.

Anticholinergic versus botulinum toxin A comparison trial for the treatment of bothersome urge urinary incontinence: ABC trial

A phase II dose-ranging study of mirabegron in patients with overactive bladder

Incorporating multiple interventions in meta-analysis: an evaluation of the mixed treatment comparison with the adjusted indirect comparison.

Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder.

Global prevalence and economic burden of urgency urinary incontinence: a systematic review.

Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.

P304

1824-1831

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/NAU.23189

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P Toozs-Hobson

P577

2017-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28220521

http://www.w3.org/2001/XMLSchema#string

Indirect treatment comparison (ITC) of medical therapies for an overactive bladder.

about

P2860

P2860

Indirect treatment comparison (ITC) of medical therapies for an overactive bladder.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698